- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Publication
Article
Dermatology Times
Psoriasis physician survey highlights need for effective therapies
Author(s):
A recent survey asks dermatologists who treat patients with moderate to severe psoriasis about the greatest unmet needs of this patient group. Here's what physicians had to say.
A survey of 75 dermatologists who treat patients with moderate to severe psoriasis shows that among the greatest of unmet patient needs includes, in this order, the lack of safe and effective oral therapies, affordable treatments covered by insurance, treatment that is effective in maintaining long-term remission and lastly, topical treatments that work.
The survey, which was conducted between Nov. 21-26, was developed by InCrowd, a market intelligence firm specializing in healthcare.
This group of physicians report treating an average of 79 patients with moderate to severe psoriasis over the course of three months; and, they described great interest in the development of new therapeutics, including IL-17/23/31 agents, JAK inhibitors and TYK2 inhibitors.
Of biologic and other non-biologic therapies doctors prescribe, these include: corticosteroids (58%); biologics (48%); generalized OTC products (22%); phototherapy (13%); PDE4 inhibitors (13%); topical or oral retinoids (11%); and, antibiotics (4%).
And, finally, in terms of treatment choice, Humira and Stelara were the most popular.
